Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Efficacy of Vafidemstat in Experimental Autoimmune Encepha-Lomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis

  • Cavalcanti, F.
  • González-Rey, Elena
  • Delgado, M.
  • Falo, CP
  • Mestre, Leyre
  • Guaza, Carmen
  • O´Valle, F.
  • Lufino, Michele M. P.
  • Xaus, Jordi
  • Mascaró, C.
  • Lunardi, Serena
  • Sacilotto, Natalia
  • Dessanti, Paola
  • Rotllant, David
  • Navarro, Xavier
  • Herrando-Grabulosa, Mireia
  • Buesa, Carlos
  • Maes, Tamara
Lysine specific demethylase 1 (LSD1; also known as KDM1A), is an epigenetic modulator that modifies the histone methylation status. KDM1A forms a part of protein complexes that regulate the expression of genes involved in the onset and progression of diseases such as cancer, central nervous system (CNS) disorders, viral infections, and others. Vafidemstat (ORY-2001) is a clinical stage inhibitor of KDM1A in development for the treatment of neurodegenerative and psychiatric diseases. However, the role of ORY-2001 targeting KDM1A in neuroinflammation remains to be explored. Here, we investigated the effect of ORY-2001 on immune-mediated and virus-induced encephalomyelitis, two experimental models of multiple sclerosis and neuronal damage. Oral ad-ministration of ORY-2001 ameliorated clinical signs, reduced lymphocyte egress and infiltration of immune cells into the spinal cord, and prevented demyelination. Interestingly, ORY-2001 was more effective and/or faster acting than a sphingosine 1-phosphate receptor antagonist in the effector phase of the disease and reduced the inflammatory gene expression signature characteristic ofEAE in the CNS of mice more potently. In addition, ORY-2001 induced gene expression changes con-cordant with a potential neuroprotective function in the brain and spinal cord and reduced neuronal glutamate excitotoxicity-derived damage in explants. These results pointed to ORY-2001 as a promising CNS epigenetic drug able to target neuroinflammatory and neurodegenerative diseases and provided preclinical support for the subsequent design of early-stage clinical trials., This research funded by Oryzon Genomics, S.A. and partially supported by RETOS: (RTC2016-4955-1); EUROSTAR II: EMTherapy (CIIP-20152001/E!9683) and CDTI: EDOTEM (IDI-20180117).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations

  • Maes, Tamara|||0000-0001-5104-6867
  • Mascaró, Cristina
  • Rotllant, David|||0000-0002-1186-4918
  • Lufino, Michele Matteo Pio
  • Estiarte, Angels|||0000-0001-8687-3395
  • Guibourt, Nathalie
  • Cavalcanti, Fernando
  • Griñan-Ferré, Christian
  • Pallàs, Mercè|||0000-0003-3095-4254
  • Nadal i Alemany, Roser|||0000-0001-8972-2525
  • Armario Garcia, Antonio|||0000-0001-9524-3635
  • Ferrer, Isidro|||0000-0001-9888-8754
  • Ortega, Alberto
  • Valls, Nuria
  • Fyfe, Matthew|||0000-0001-5258-5379
  • Martinell, Marc
  • Castro Palomino, Julio César
  • Buesa, Carlos|||0000-0001-6293-2514
Transcription disequilibria are characteristic of many neurodegenerative diseases. The activity-evoked transcription of immediate early genes (IEGs), important for neuronal plasticity, memory and behavior, is altered in CNS diseases and governed by epigenetic modulation. KDM1A, a histone 3 lysine 4 demethylase that forms part of transcription regulation complexes, has been implicated in the control of IEG transcription. Here we report the development of vafidemstat (ORY-2001), a brain penetrant inhibitor of KDM1A and MAOB. ORY-2001 efficiently inhibits brain KDM1A at doses suitable for long term treatment, and corrects memory deficit as assessed in the novel object recognition testing in the Senescence Accelerated Mouse Prone 8 (SAMP8) model for accelerated aging and Alzheimer's disease. Comparison with a selective KDM1A or MAOB inhibitor reveals that KDM1A inhibition is key for efficacy. ORY-2001 further corrects behavior alterations including aggression and social interaction deficits in SAMP8 mice and social avoidance in the rat rearing isolation model. ORY-2001 increases the responsiveness of IEGs, induces genes required for cognitive function and reduces a neuroinflammatory signature in SAMP8 mice. Multiple genes modulated by ORY-2001 are differentially expressed in Late Onset Alzheimer's Disease. Most strikingly, the amplifier of inflammation S100A9 is highly expressed in LOAD and in the hippocampus of SAMP8 mice, and down-regulated by ORY-2001. ORY-2001 is currently in multiple Phase IIa studies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis

  • Cavalcanti, Fernando
  • Gonzalez-Rey, Elena|||0000-0003-3917-9020
  • Delgado, Mario|||0000-0003-1893-5982
  • Falo, Clara P.
  • Mestre, Leyre|||0000-0001-6970-2316
  • Guaza, Carmen|||0000-0003-3240-9807
  • O'Valle, Francisco|||0000-0001-9207-2287
  • Lufino, Michele M. P.
  • Xaus, Jordi|||0000-0002-6896-8814
  • Mascaró, Cristina
  • Lunardi, Serena
  • Sacilotto, Natalia
  • Dessanti, Paola
  • Rotllant, David|||0000-0002-1186-4918
  • Navarro, X. (Xavier)|||0000-0001-9849-902X
  • Herrando-Grabulosa, Mireia|||0000-0002-6685-3220
  • Buesa, Carlos|||0000-0001-6293-2514
  • Maes, Tamara|||0000-0001-5104-6867
Lysine specific demethylase 1 (LSD1; also known as KDM1A), is an epigenetic modulator that modifies the histone methylation status. KDM1A forms a part of protein complexes that regulate the expression of genes involved in the onset and progression of diseases such as cancer, central nervous system (CNS) disorders, viral infections, and others. Vafidemstat (ORY-2001) is a clinical stage inhibitor of KDM1A in development for the treatment of neurodegenerative and psychiatric diseases. However, the role of ORY-2001 targeting KDM1A in neuroinflammation remains to be explored. Here, we investigated the effect of ORY-2001 on immune-mediated and virus-induced encephalomyelitis, two experimental models of multiple sclerosis and neuronal damage. Oral administration of ORY-2001 ameliorated clinical signs, reduced lymphocyte egress and infiltration of immune cells into the spinal cord, and prevented demyelination. Interestingly, ORY-2001 was more effective and/or faster acting than a sphingosine 1-phosphate receptor antagonist in the effector phase of the disease and reduced the inflammatory gene expression signature characteristic ofEAE in the CNS of mice more potently. In addition, ORY-2001 induced gene expression changes concordant with a potential neuroprotective function in the brain and spinal cord and reduced neuronal glutamate excitotoxicity-derived damage in explants. These results pointed to ORY-2001 as a promising CNS epigenetic drug able to target neuroinflammatory and neurodegenerative diseases and provided preclinical support for the subsequent design of early-stage clinical trials.